Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Asundexian in Renal Impairment
NCT04510987Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of asundexian in thromboembolism, myocardial infarction (MI), Atrial fibrillation (AFib) and 1 more (2 arms), sponsored by Bayer. Primary endpoints: Maximum Plasma Concentration at 96 hours, Area Under the Curve at 96 hours and 2 more. Started Aug 2020; status: completed.
02
Drugs
asundexian
03
Conditions
thromboembolismmyocardial infarction (MI)Atrial fibrillation (AFib)ischemic stroke
Beyond the preview
Go deeper on NCT04510987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510987.